Hood River Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Hood River Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-66,820	Closed	-$6.66M	–	130
2021 Q1	$6.66M	Sell	66,820 -6,194	-8%	-$722K	0.21%	96
2020 Q4	$9.03M	Buy	73,014 +1,324	+2%	+$174K	0.3%	88
2020 Q3	$6.98M	Sell	71,690 -7,210	-9%	-$901K	0.3%	88
2020 Q2	$12.3M	Buy	+78,900	New	+$12M	0.55%	70

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Hood River Capital Management's RETA Position: Q2 2021 in Review

Hood River Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2021, closing a stake of 66,820 shares — an estimated $6.66M sold.

Hood River Capital Management first reported a position in RETA in Q2 2020 and held it in 4 quarters. The position peaked at $12.3M in Q2 2020. 194 funds tracked by Wall St. Rank hold RETA as of Q2 2021.

Hood River Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2021 after selling out during the quarter.
Hood River Capital Management sold 66,820 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2021, an estimated $6.66M.
Hood River Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2020 and held it in 4 quarters.
Hood River Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $12.3M in Q2 2020.
194 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2021.

Based on Hood River Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.